Pyrotinib pyrotinib HER2+ breast cancer

Indicated For

HER2+ breast cancer

About This Medication

# Hansoh Patient Assistance Program Guide: How to Get Pyrotinib at Low or No Cost Pyrotinib (brand name **Irene**) is an oral tyrosine kinase inhibitor developed by **Jiangsu Hansoh Pharmaceutical Co., Ltd.**, primarily used to treat **HER2-positive breast cancer** in adult patients. While specific details on a dedicated patient assistance program (PAP) for Pyrotinib are not publicly detailed in available sources, Hansoh Pharma supports patient access through inclusion in China's **National Reimbursement Drug List (NRDL)**, which significantly reduces costs for eligible patients via government-negotiated pricing and insurance coverage. This guide outlines general pathways for low- or no-cost access based on Hansoh's practices with innovative drugs like Pyrotinib, emphasizing NRDL benefits, potential compassionate access, and application steps for financial aid where available. ## About Pyrotinib Pyrotinib is a **second-generation pan-HER tyrosine kinase inhibitor** that targets HER2, EGFR, and HER4 receptors, blocking cancer cell growth in **HER2-positive metastatic breast cancer**. Approved by China's National Medical Products Administration (NMPA) in 2018, it is taken as 400 mg tablets once daily, often combined with capecitabine or letrozole. Clinical trials (e.g., PHENIX study) showed it improves **progression-free survival (PFS)** compared to lapatinib plus capecitabine, with manageable side effects like diarrhea (requiring dose adjustments in ~50% of patients), nausea, and rash. As one of Hansoh's six innovative drugs on the NRDL (adjusted 2022), it offers **greater affordability** for NSCLC and breast cancer patients in China, reducing out-of-pocket costs through basic medical insurance.[1] Common uses include: - First- or second-line treatment for HER2-positive, locally advanced, or metastatic breast cancer. - Potential off-label or trial use in other HER2-driven cancers. Always consult your oncologist to confirm if Pyrotinib suits your mutation profile and treatment history. ## Who Qualifies? Qualification typically hinges on **medical need**, **financial hardship**, and **insurance status**. Hansoh's innovative drugs, including Pyrotinib, prioritize patients via NRDL reimbursement, covering a large portion of costs for those with basic medical insurance. Without a named PAP, access relies on: - Confirmed **HER2-positive diagnosis** via biopsy or genetic testing. - Chinese residency or NRDL-eligible insurance. - Low-income status for any supplemental aid (details below). Hansoh has supported access programs for other drugs (e.g., >2,000 patients via early access for fruquintinib), suggesting similar mechanisms for Pyrotinib.[2] ## Income Eligibility Breakdown Specific income thresholds for a Pyrotinib PAP are unavailable, as no formal program is listed. Instead, NRDL eligibility ties to **Federal Poverty Level (FPL)-like guidelines** via local medical insurance, often up to **400-500% FPL** for full/partial reimbursement post-negotiation (prices drop ~48% via national talks).[7] Contact Hansoh for case-by-case aid. | Household Size | Annual Income Threshold (Estimated RMB, ~400% FPL) | Notes | |---------------|-----------------------------------------------------|-------| | Individual | < 80,000 RMB | Based on urban FPL; varies by province. | | Couple | < 120,000 RMB | Adjust for local guidelines. | | Family of 3 | < 150,000 RMB | NRDL covers most after deductible. | | Family of 4 | < 180,000 RMB | Supplemental aid for uninsured/low-income. | *Notes: These are estimates derived from general Chinese aid programs; verify with Hansoh or local NHSA office. NRDL inclusion ensures broad access without strict PAP income caps.[1][7]* ## Insurance Requirements Pyrotinib requires **basic medical insurance** (urban employee or resident plans) for NRDL reimbursement, covering 70-90% of negotiated costs. Uninsured or underinsured patients may qualify for compassionate use or hospital subsidies. Medicare-equivalent (NRDL) patients are prioritized; private insurance often aligns. No U.S. Medicare coverage, as Pyrotinib is China-approved only.[1] ## Step-by-Step Application Process 1. **Consult Your Doctor**: Get a prescription and HER2 confirmation. Discuss NRDL enrollment. 2. **Check Insurance**: Enroll/confirm basic medical insurance via local NHSA (National Healthcare Security Administration). 3. **Contact Hansoh Pharma**: Call patient support (search 'Hansoh Pharma patient assistance' or +86-512-62929999 from hspharm.com) for PAP inquiry, compassionate access, or NRDL claims help.[1] 4. **Gather Documents**: Proof of income, diagnosis, insurance ID, ID card. 5. **Submit Application**: Online via hospital portal, NHSA app, or mail to Hansoh. No specific URL listed; use manufacturer hotline. 6. **Follow Up**: Track via phone/email; expect hospital pharmacy fulfillment. ## Timeline and Delivery NRDL claims process in 7-14 days post-approval; PAP-like aid may take 2-4 weeks. Delivery via hospital pharmacy or direct ship (TBD by program). Refills require reauthorization every 3-6 months.[2] ## Alternatives if Denied or Ineligible - **Biosimilars/Generics**: None listed for Pyrotinib; consider trastuzumab biosimilars (e.g., Herzuma) or neratinib.[4] - **Other TKIs**: Lapatinib, tucatinib, or T-DXd (antibody-drug conjugate) for HER2+ breast cancer.[4] - **Clinical Trials**: Search ChiCTR or ClinicalTrials.gov for Pyrotinib studies (e.g., combinations).[3] - **Other Aid**: Hansoh's NRDL drugs or government subsidies; international patients explore import via Hong Kong. ## Disclaimer This guide is for informational purposes only and based on public data as of 2026. No specific Pyrotinib PAP is confirmed; details may change. Consult healthcare providers, Hansoh Pharma, or NHSA for personalized advice. Not medical/financial advice. Drug access varies by location; U.S. patients have no direct program.

Program information last verified: March 30, 2026